<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39329791</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2079-6374</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>Biosensors</Title><ISOAbbreviation>Biosensors (Basel)</ISOAbbreviation></Journal><ArticleTitle>Overcoming Limited Access to Virus Infection Rapid Testing: Development of a Lateral Flow Test for SARS-CoV-2 with Locally Available Resources.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">416</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/bios14090416</ELocationID><Abstract><AbstractText>The COVID-19 pandemic highlighted testing inequities in developing countries. Lack of lateral flow test (LFT) manufacturing capacity was a major COVID-19 response bottleneck in low- and middle-income regions. Here we report the development of an open-access LFT for SARS-CoV-2 detection comparable to commercial tests that requires only locally available supplies. The main critical resource is a locally developed horse polyclonal antibody (pAb) whose sensitivity and selectivity are greatly enhanced by affinity purification. We demonstrate that these Abs can perform similarly to commercial monoclonal antibodies (mAbs), as well as mAbs and other pAbs developed against the same antigen. We report a workflow for test optimization using nasopharyngeal swabs collected for RT-qPCR, spiked with the inactivated virus to determine analytical performance characteristics as the limit of detection, among others. Our final prototype showed a performance similar to available tests (sensitivity of 83.3% compared to RT-qPCR, and 90.9% compared to commercial antigen tests). Finally, we discuss the possibility and the challenges of utilizing affinity-purified pAbs as an alternative for the local development of antigen tests in an outbreak context and as a tool to address inequalities in access to rapid tests.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peri Ibáñez</LastName><ForeName>Estefanía S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Laboratorio de Inmunología y Virología (LIV), Departamento de Ciencia y Tecnología, Universidad Nacional de Quilmes, B1876BXD Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), CONICET, Fundación Instituto Leloir, C1405BWE Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzeo</LastName><ForeName>Agostina</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4695-5673</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), CONICET, Fundación Instituto Leloir, C1405BWE Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), CONICET, Fundación Instituto Leloir, C1405BWE Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INQUIMAE (CONICET), Departamento de Química Inorgánica, Analítica y Química Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), C1428EGA Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juncos</LastName><ForeName>Maria Juliana</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-7576-3035</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), CONICET, Fundación Instituto Leloir, C1405BWE Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa Navarro</LastName><ForeName>Guadalupe S</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0002-4051-4749</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), CONICET, Fundación Instituto Leloir, C1405BWE Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallarés</LastName><ForeName>Horacio M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), CONICET, Fundación Instituto Leloir, C1405BWE Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolos</LastName><ForeName>Virginia J</ForeName><Initials>VJ</Initials><Identifier Source="ORCID">0009-0008-1007-0965</Identifier><AffiliationInfo><Affiliation>Universidad de Buenos Aires (UBA), Instituto de Oncología Ángel H. Roffo, Área Investigación, C1417DTB Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiszman</LastName><ForeName>Gabriel L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Universidad de Buenos Aires (UBA), Instituto de Oncología Ángel H. Roffo, Área Investigación, C1417DTB Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mundo</LastName><ForeName>Silvia L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-5263-1766</Identifier><AffiliationInfo><Affiliation>Cátedra de Inmunología, Facultad de Ciencias Veterinarias, Universidad de Buenos Aires (UBA), C1427CWN Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caramelo</LastName><ForeName>Julio J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), CONICET, Fundación Instituto Leloir, C1405BWE Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanovsky</LastName><ForeName>Marcelo J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), CONICET, Fundación Instituto Leloir, C1405BWE Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fingermann</LastName><ForeName>Matías</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Producción de Biológicos (INPB), ANLIS "Dr. Carlos G. Malbrán", C1282AFF Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castello</LastName><ForeName>Alejandro A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-0586-1702</Identifier><AffiliationInfo><Affiliation>Laboratorio de Inmunología y Virología (LIV), Departamento de Ciencia y Tecnología, Universidad Nacional de Quilmes, B1876BXD Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Medicina Traslacional, Hospital El Cruce Néstor C., Kirchner, B1888 Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Ciencias de la Salud, Universidad Nacional Arturo Jauretche, B1888 Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamarnik</LastName><ForeName>Andrea V</ForeName><Initials>AV</Initials><Identifier Source="ORCID">0000-0002-9789-4105</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), CONICET, Fundación Instituto Leloir, C1405BWE Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peinetti</LastName><ForeName>Ana S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-9304-3004</Identifier><AffiliationInfo><Affiliation>INQUIMAE (CONICET), Departamento de Química Inorgánica, Analítica y Química Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), C1428EGA Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capdevila</LastName><ForeName>Daiana A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0002-0500-1016</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), CONICET, Fundación Instituto Leloir, C1405BWE Ciudad Autónoma de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FONARSEC-KITS Antígenos N° 5</GrantID><Agency>FONARSEC</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biosensors (Basel)</MedlineTA><NlmUniqueID>101609191</NlmUniqueID><ISSNLinking>2079-6374</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">diagnostics</Keyword><Keyword MajorTopicYN="N">lateral flow tests</Keyword><Keyword MajorTopicYN="N">local development</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39329791</ArticleId><ArticleId IdType="pmc">PMC11431090</ArticleId><ArticleId IdType="doi">10.3390/bios14090416</ArticleId><ArticleId IdType="pii">bios14090416</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Budd J., Miller B.S., Weckman N.E., Cherkaoui D., Huang D., Decruz A.T., Fongwen N., Han G.-R., Broto M., Estcourt C.S., et al. Lateral Flow Test Engineering and Lessons Learned from COVID-19. Nat. Rev. Bioeng. 2023;1:13–31. doi: 10.1038/s44222-022-00007-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44222-022-00007-3</ArticleId></ArticleIdList></Reference><Reference><Citation>BinaxNOWTM COVID-19 Ag Card  FDA.  [(accessed on 11 August 2024)];2020  Available online:  https://www.fda.gov/media/141570/download.</Citation></Reference><Reference><Citation>Parolo C., Sena-Torralba A., Bergua J.F., Calucho E., Fuentes-Chust C., Hu L., Rivas L., Álvarez-Diduk R., Nguyen E.P., Cinti S., et al. Tutorial: Design and Fabrication of Nanoparticle-Based Lateral-Flow Immunoassays. Nat. Protoc. 2020;15:3788–3816. doi: 10.1038/s41596-020-0357-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-0357-x</ArticleId><ArticleId IdType="pubmed">33097926</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant B.D., Anderson C.E., Alonzo L.F., Garing S.H., Williford J.R., Baughman T.A., Rivera R., Glukhova V.A., Boyle D.S., Dewan P.K., et al. A SARS-CoV-2 Coronavirus Nucleocapsid Protein Antigen-Detecting Lateral Flow Assay. PLoS ONE. 2021;16:e0258819. doi: 10.1371/journal.pone.0258819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0258819</ArticleId><ArticleId IdType="pmc">PMC8580225</ArticleId><ArticleId IdType="pubmed">34758052</ArticleId></ArticleIdList></Reference><Reference><Citation>Pucca M.B., Cerni F.A., Janke R., Bermúdez-Méndez E., Ledsgaard L., Laustsen A.H. History of Envenoming Therapy and Current Perspectives. Front. Immunol. 2019;10:1598. doi: 10.3389/fimmu.2019.01598.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01598</ArticleId><ArticleId IdType="pmc">PMC6635583</ArticleId><ArticleId IdType="pubmed">31354735</ArticleId></ArticleIdList></Reference><Reference><Citation>Potet J., Beran D., Ray N., Alcoba G., Habib A.G., Iliyasu G., Waldmann B., Ralph R., Faiz M.A., Monteiro W.M., et al. Access to Antivenoms in the Developing World: A Multidisciplinary Analysis. Toxicon: X. 2021;12:100086. doi: 10.1016/j.toxcx.2021.100086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxcx.2021.100086</ArticleId><ArticleId IdType="pmc">PMC8578041</ArticleId><ArticleId IdType="pubmed">34786555</ArticleId></ArticleIdList></Reference><Reference><Citation>Chippaux J.-P., Massougbodji A., Habib A.G. The WHO Strategy for Prevention and Control of Snakebite Envenoming: A Sub-Saharan Africa Plan. J. Venom. Anim. Toxins Incl. Trop. Dis. 2019;25:e20190083. doi: 10.1590/1678-9199-jvatitd-2019-0083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1678-9199-jvatitd-2019-0083</ArticleId><ArticleId IdType="pmc">PMC6892564</ArticleId><ArticleId IdType="pubmed">31839803</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutiérrez J.M. Global Availability of Antivenoms: The Relevance of Public Manufacturing Laboratories. Toxins. 2019;11:5. doi: 10.3390/toxins11010005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins11010005</ArticleId><ArticleId IdType="pmc">PMC6356591</ArticleId><ArticleId IdType="pubmed">30586868</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan H.W., Vigilato M.A.N., Pompei J.C.A., Gutiérrez J.M., Red de Laboratorios Públicos Productores de Antivenenos de América Latina (RELAPA) Situación de Los Laboratorios Públicos Productores de Antivenenos En América Latina. Rev. Panam. Salud Publica. 2019;43:e92. doi: 10.26633/RPSP.2019.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.26633/RPSP.2019.92</ArticleId><ArticleId IdType="pmc">PMC6863067</ArticleId><ArticleId IdType="pubmed">31772565</ArticleId></ArticleIdList></Reference><Reference><Citation>Temprano G., Angeleri P., Dokmetjian J.C. La Producción Pública de Antivenenos En La Región de Las Américas Como Factor Clave En Su Accesibilidad.  [(accessed on 11 August 2024)];Rev. Panam. Salud Publica. 2017 41:e109.  doi: 10.26633/RPSP.2017.109. Available online:  https://iris.paho.org/handle/10665.2/34170.</Citation><ArticleIdList><ArticleId IdType="doi">10.26633/RPSP.2017.109</ArticleId><ArticleId IdType="pmc">PMC6645312</ArticleId><ArticleId IdType="pubmed">28902267</ArticleId></ArticleIdList></Reference><Reference><Citation>Byzova N.A., Urusov A.E., Zherdev A.V., Dzantiev B.B. Multiplex Highly Sensitive Immunochromatographic Assay Based on the Use of Nonprocessed Antisera. Anal. Bioanal. Chem. 2018;410:1903–1910. doi: 10.1007/s00216-018-0853-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-018-0853-9</ArticleId><ArticleId IdType="pubmed">29353430</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantera J.L., Cate D.M., Golden A., Peck R.B., Lillis L.L., Domingo G.J., Murphy E., Barnhart B.C., Anderson C.A., Alonzo L.F., et al. Screening Antibodies Raised against the Spike Glycoprotein of SARS-CoV-2 to Support the Development of Rapid Antigen Assays. ACS Omega. 2021;6:20139–20148. doi: 10.1021/acsomega.1c01321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.1c01321</ArticleId><ArticleId IdType="pmc">PMC8340086</ArticleId><ArticleId IdType="pubmed">34373846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo-Alfaro L., Lorente-Montalvo P., Cañellas M., Carandell E., Oliver A., Rojo E., Riera B., Llobera J., Bulilete O., Leiva A., et al. Diagnostic Accuracy of PanbioTM Rapid Antigen Test for SARS-CoV-2 in Paediatric Population. BMC Pediatr. 2023;23:433. doi: 10.1186/s12887-023-04201-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-023-04201-z</ArticleId><ArticleId IdType="pmc">PMC10463935</ArticleId><ArticleId IdType="pubmed">37644389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojeda D.S., Ledesma M.M.G.L., Pallarés H.M., Navarro G.S.C., Sanchez L., Perazzi B., Villordo S.M., Alvarez D.E., Group B.W., Echavarria M., et al. Emergency Response for Evaluating SARS-CoV-2 Immune Status, Seroprevalence and Convalescent Plasma in Argentina. PLoS Pathog. 2021;17:e1009161. doi: 10.1371/journal.ppat.1009161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009161</ArticleId><ArticleId IdType="pmc">PMC7808630</ArticleId><ArticleId IdType="pubmed">33444413</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres C., Mojsiejczuk L., Acuña D., Alexay S., Amadio A., Aulicino P., Debat H., Fay F., Fernández F., Giri A.A., et al. Cost-Effective Method to Perform SARS-CoV-2 Variant Surveillance: Detection of Alpha, Gamma, Lambda, Delta, Epsilon, and Zeta in Argentina. Front. Med. 2021;8:755463. doi: 10.3389/fmed.2021.755463.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.755463</ArticleId><ArticleId IdType="pmc">PMC8703000</ArticleId><ArticleId IdType="pubmed">34957143</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant B.D., Anderson C.E., Williford J.R., Alonzo L.F., Glukhova V.A., Boyle D.S., Weigl B.H., Nichols K.P. SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents. Anal. Chem. 2020;92:11305–11309. doi: 10.1021/acs.analchem.0c01975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.0c01975</ArticleId><ArticleId IdType="pubmed">32605363</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker A.N., Richards S.-J., Guy C.S., Congdon T.R., Hasan M., Zwetsloot A.J., Gallo A., Lewandowski J.R., Stansfeld P.J., Straube A., et al. The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device. ACS Cent. Sci. 2020;6:2046–2052. doi: 10.1021/acscentsci.0c00855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.0c00855</ArticleId><ArticleId IdType="pmc">PMC7523238</ArticleId><ArticleId IdType="pubmed">33269329</ArticleId></ArticleIdList></Reference><Reference><Citation>Salcedo N., Reddy A., Gomez A.R., Bosch I., Herrera B.B. Monoclonal Antibody Pairs against SARS-CoV-2 for Rapid Antigen Test Development. PLoS Neglected Trop. Dis. 2022;16:e0010311. doi: 10.1371/journal.pntd.0010311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0010311</ArticleId><ArticleId IdType="pmc">PMC9004783</ArticleId><ArticleId IdType="pubmed">35358198</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., Peacock S.J., et al. SARS-CoV-2 Variants, Spike Mutations and Immune Escape. Nat. Rev. Microbiol. 2021;19:409–424. doi: 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Guruprasad L. Human SARS CoV-2 Spike Protein Mutations. Proteins: Struct. Funct. Bioinform. 2021;89:569–576. doi: 10.1002/prot.26042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.26042</ArticleId><ArticleId IdType="pmc">PMC8014176</ArticleId><ArticleId IdType="pubmed">33423311</ArticleId></ArticleIdList></Reference><Reference><Citation>Das D., Kammila S., Suresh M.R. Development, Characterization, and Application of Monoclonal Antibodies against Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein. Clin. Vaccine Immunol. 2010;17:2033–2036. doi: 10.1128/CVI.00293-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00293-10</ArticleId><ArticleId IdType="pmc">PMC3008203</ArticleId><ArticleId IdType="pubmed">20926700</ArticleId></ArticleIdList></Reference><Reference><Citation>Rak A., Gorbunov N., Kostevich V., Sokolov A., Prokopenko P., Rudenko L., Isakova-Sivak I. Assessment of Immunogenic and Antigenic Properties of Recombinant Nucleocapsid Proteins of Five SARS-CoV-2 Variants in a Mouse Model. Viruses. 2023;15:230. doi: 10.3390/v15010230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010230</ArticleId><ArticleId IdType="pmc">PMC9861333</ArticleId><ArticleId IdType="pubmed">36680269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Z., Cao Y., Liu W., Li J. The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses. 2021;13:1115. doi: 10.3390/v13061115.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061115</ArticleId><ArticleId IdType="pmc">PMC8227405</ArticleId><ArticleId IdType="pubmed">34200602</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Fang X., Liu X., Ou H., Zhang H., Wang J., Li Q., Cheng H., Zhang W., Luo Z. Discovery of Sandwich Type COVID-19 Nucleocapsid Protein DNA Aptamers. Chem. Commun. 2020;56:10235–10238. doi: 10.1039/D0CC03993D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0CC03993D</ArticleId><ArticleId IdType="pubmed">32756614</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez Lopez Ledesma M.M., Sanchez L., Ojeda D.S., Oviedo Rouco S., Rossi A.H., Varese A., Mazzitelli I., Pascuale C.A., Miglietta E.A., Rodríguez P.E., et al. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time. mBio. 2022;13:e03442-21. doi: 10.1128/mbio.03442-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03442-21</ArticleId><ArticleId IdType="pmc">PMC8787469</ArticleId><ArticleId IdType="pubmed">35073758</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kaabi N., Zhang Y., Xia S., Yang Y., Al Qahtani M.M., Abdulrazzaq N., Al Nusair M., Hassany M., Jawad J.S., Abdalla J., et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. JAMA. 2021;326:35–45. doi: 10.1001/jama.2021.8565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.8565</ArticleId><ArticleId IdType="pmc">PMC8156175</ArticleId><ArticleId IdType="pubmed">34037666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadj Hassine I. Covid-19 Vaccines and Variants of Concern: A Review. Rev. Med. Virol. 2022;32:e2313. doi: 10.1002/rmv.2313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2313</ArticleId><ArticleId IdType="pmc">PMC8646685</ArticleId><ArticleId IdType="pubmed">34755408</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes M.P.d.B., Linhares J.H.R., dos Santos T.P., Pereira R.C., Santos R.T., da Silva S.A., Souza M.C.d.O., da Silva J.F.A., Trindade G.F., Gomes V.S., et al. Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials. Viruses. 2023;15:1486. doi: 10.3390/v15071486.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15071486</ArticleId><ArticleId IdType="pmc">PMC10386713</ArticleId><ArticleId IdType="pubmed">37515173</ArticleId></ArticleIdList></Reference><Reference><Citation>Brizuela M.E., Goñi S.E., Cardama G.A., Zinni M.A., Castello A.A., Sommese L.M., Farina H.G. Correlation of SARS-CoV-2 Viral Load and Clinical Evolution of Pediatric Patients in a General Hospital From Buenos Aires, Argentina. Front. Pediatr. 2022;10:883395. doi: 10.3389/fped.2022.883395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.883395</ArticleId><ArticleId IdType="pmc">PMC9301330</ArticleId><ArticleId IdType="pubmed">35874580</ArticleId></ArticleIdList></Reference><Reference><Citation>González Viacava M.B., Varese A., Mazzitelli I., Lanari L., Ávila L., García Vampa M.J., Geffner J., Cascone O., Dokmetjian J.C., de Roodt A.R., et al. Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera. Antibodies. 2022;11:3. doi: 10.3390/antib11010003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib11010003</ArticleId><ArticleId IdType="pmc">PMC8788445</ArticleId><ArticleId IdType="pubmed">35076465</ArticleId></ArticleIdList></Reference><Reference><Citation>De Simone E.A., Saccodossi N., Ferrari A., Leoni J. Development of ELISAs for the Measurement of IgM and IgG Subclasses in Sera from Llamas (Lama glama) and Assessment of the Humoral Immune Response against Different Antigens. Vet. Immunol. Immunopathol. 2008;126:64–73. doi: 10.1016/j.vetimm.2008.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetimm.2008.06.015</ArticleId><ArticleId IdType="pubmed">18692907</ArticleId></ArticleIdList></Reference><Reference><Citation>Nudel B.C., Perdoménico C., Iácono R., Cascone O. Optimization by Factorial Analysis of Caprylic Acid Precipitation of Non-Immunoglobulins from Hyperimmune Equine Plasma for Antivenom Preparation. Toxicon. 2012;59:68–73. doi: 10.1016/j.toxicon.2011.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxicon.2011.10.014</ArticleId><ArticleId IdType="pubmed">22079738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimling J., Maier M., Okenve B., Kotaidis V., Ballot H., Plech A. Turkevich Method for Gold Nanoparticle Synthesis Revisited. J. Phys. Chem. B. 2006;110:15700–15707. doi: 10.1021/jp061667w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jp061667w</ArticleId><ArticleId IdType="pubmed">16898714</ArticleId></ArticleIdList></Reference><Reference><Citation>Armbruster D.A., Pry T. Limit of Blank, Limit of Detection and Limit of Quantitation. Clin. Biochem. Rev. 2008;29:S49–S52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2556583</ArticleId><ArticleId IdType="pubmed">18852857</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriquin G., Davidson R.J., Hatchette T.F., Head B.M., Mejia E., Becker M.G., Meyers A., Sandstrom P., Hatchette J., Block A., et al. Generation of False-Positive SARS-CoV-2 Antigen Results with Testing Conditions Outside Manufacturer Recommendations: A Scientific Approach to Pandemic Misinformation. Microbiol. Spectr. 2021;9:e00683-21. doi: 10.1128/Spectrum.00683-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00683-21</ArticleId><ArticleId IdType="pmc">PMC8528119</ArticleId><ArticleId IdType="pubmed">34668722</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacot D., Greub G., Jaton K., Opota O. Viral Load of SARS-CoV-2 across Patients and Compared to Other Respiratory Viruses. Microbes Infect. 2020;22:617–621. doi: 10.1016/j.micinf.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7476607</ArticleId><ArticleId IdType="pubmed">32911086</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C.-G., Lee K.-M., Hsiao M.-J., Yang S.-L., Huang P.-N., Gong Y.-N., Hsieh T.-H., Huang P.-W., Lin Y.-J., Liu Y.-C., et al. Culture-Based Virus Isolation To Evaluate Potential Infectivity of Clinical Specimens Tested for COVID-19. J. Clin. Microbiol. 2020;58 doi: 10.1128/JCM.01068-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01068-20</ArticleId><ArticleId IdType="pmc">PMC7383522</ArticleId><ArticleId IdType="pubmed">32518072</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng T., Dong L., Feng X., Yang Y., Wang X., Niu C., Liang Z., Qu W., Zou Q., Dai X., et al. Relationship between SARS-CoV-2 Nucleocapsid Protein and N Gene and Its Application in Antigen Testing Kits Evaluation. Talanta. 2023;258:124462. doi: 10.1016/j.talanta.2023.124462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.talanta.2023.124462</ArticleId><ArticleId IdType="pmc">PMC10029331</ArticleId><ArticleId IdType="pubmed">36963149</ArticleId></ArticleIdList></Reference><Reference><Citation>GeneTex SARS-CoV-2 (COVID-19) Nucleocapsid Antibody.  [(accessed on 19 August 2024)].  Available online:  https://www.genetex.com/Product/Detail/SARS-CoV-2-COVID-19-Nucleocapsid-antibody/GTX135357?srsltid=AfmBOoqhuSrW0yt-KPo8-vy81qvpQH2WDl1sKzvoxnYZsUWTcAT9oif8#references.</Citation></Reference><Reference><Citation>CD—Creative Diagnostics—Human Anti-SARS-CoV-2 Nucleoprotein Monoclonal Antibody for ELISA.  [(accessed on 19 August 2024)].  Available online:  https://www.creative-diagnostics.com/sars-cov-2-nucleoprotein-antibody-277914-144.htm.</Citation></Reference><Reference><Citation>GeneScript—MonoRabTM SARS-CoV-2 Nucleocapsid Antibody (N34), mAb, Rabbit.  [(accessed on 19 August 2024)].  Available online:  https://www.genscript.com/antibody/A02136-MonoRab_SARS_CoV_2_Nucleocapsid_Antibody_N34_mAb_Rabbit.html?_gl=1*16y79ep*_up*MQ..&amp;gclid=Cj0KCQjw2ou2BhCCARIsANAwM2FDWuTFnTzJ7T1Au-ZS7HGCIVjoF__HgD8wll-0NJkmxdWBlceb8ZQaAkcVEALw_wcB.</Citation></Reference><Reference><Citation>Zhang Y., Juhas M., Kwok C.K. Aptamers Targeting SARS-COV-2: A Promising Tool to Fight against COVID-19. Trends Biotechnol. 2023;41:528–544. doi: 10.1016/j.tibtech.2022.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2022.07.012</ArticleId><ArticleId IdType="pmc">PMC9340053</ArticleId><ArticleId IdType="pubmed">35995601</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Chen X., Zhang J., Tian W., Liu S., Chun-Yee Tam R., Yang C., Song Y. Aptamer-Based Strategies against SARS-CoV-2 Viruses. BMEMat. 2023;1:e12024. doi: 10.1002/bmm2.12024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bmm2.12024</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty B., Das S., Gupta A., Xiong Y., Vyshnavi T.-V., Kizer M.E., Duan J., Chandrasekaran A.R., Wang X. Aptamers for Viral Detection and Inhibition. ACS Infect. Dis. 2022;8:667–692. doi: 10.1021/acsinfecdis.1c00546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.1c00546</ArticleId><ArticleId IdType="pmc">PMC8905934</ArticleId><ArticleId IdType="pubmed">35220716</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., Wang J., Chen L., Chen H., Dang S., Li F. Aptamer-Based Assembly Systems for SARS-CoV-2 Detection and Therapeutics. Chem. Soc. Rev. 2024;53:6830–6859. doi: 10.1039/D3CS00774J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D3CS00774J</ArticleId><ArticleId IdType="pubmed">38829187</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M., Li C., Ye G., Shen C., Shi H., Zhong L., Tian Y., Zhao M., Wu P., Hussain A., et al. Aptamers Targeting SARS-CoV-2 Nucleocapsid Protein Exhibit Potential Anti Pan-Coronavirus Activity. Signal Transduct. Target. Ther. 2024;9:40. doi: 10.1038/s41392-024-01748-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-024-01748-w</ArticleId><ArticleId IdType="pmc">PMC10866937</ArticleId><ArticleId IdType="pubmed">38355661</ArticleId></ArticleIdList></Reference><Reference><Citation>Poolsup S., Zaripov E., Hüttmann N., Minic Z., Artyushenko P.V., Shchugoreva I.A., Tomilin F.N., Kichkailo A.S., Berezovski M.V. Discovery of DNA Aptamers Targeting SARS-CoV-2 Nucleocapsid Protein and Protein-Binding Epitopes for Label-Free COVID-19 Diagnostics. Mol. Ther.—Nucleic Acids. 2023;31:731–743. doi: 10.1016/j.omtn.2023.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2023.02.010</ArticleId><ArticleId IdType="pmc">PMC9927813</ArticleId><ArticleId IdType="pubmed">36816615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan L., Granade T., Liu Y., Wei X., Youngpairoj A., Sullivan V., Johnson J., Bischof J. Development and Optimization of Thermal Contrast Amplification Lateral Flow Immunoassays for Ultrasensitive HIV P24 Protein Detection. Microsyst. Nanoeng. 2020;6:54. doi: 10.1038/s41378-020-0168-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41378-020-0168-9</ArticleId><ArticleId IdType="pmc">PMC8433161</ArticleId><ArticleId IdType="pubmed">34567665</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zhan L., Qin Z., Sackrison J., Bischof J.C. Ultrasensitive and Highly Specific Lateral Flow Assays for Point-of-Care Diagnosis. ACS Nano. 2021;15:3593–3611. doi: 10.1021/acsnano.0c10035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.0c10035</ArticleId><ArticleId IdType="pubmed">33607867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagström A.E.V., Garvey G., Paterson A.S., Dhamane S., Adhikari M., Estes M.K., Strych U., Kourentzi K., Atmar R.L., Willson R.C. Sensitive Detection of Norovirus Using Phage Nanoparticle Reporters in Lateral-Flow Assay. PLoS ONE. 2015;10:e0126571. doi: 10.1371/journal.pone.0126571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0126571</ArticleId><ArticleId IdType="pmc">PMC4433186</ArticleId><ArticleId IdType="pubmed">25978622</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.S., Kim Y.T., Hong S.B., Kim J., Heo N.S., Lee M.-K., Lee S.J., Kim B.I., Kim I.S., Huh Y.S., et al. Development of Lateral Flow Assay Based on Size-Controlled Gold Nanoparticles for Detection of Hepatitis B Surface Antigen. Sensors. 2016;16:2154. doi: 10.3390/s16122154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/s16122154</ArticleId><ArticleId IdType="pmc">PMC5191134</ArticleId><ArticleId IdType="pubmed">27999291</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Liu C., Machain-Williams C., Martinez-Acuña N., Lozano-Sepulveda S., Galan-Huerta K., Arellanos-Soto D., Meléndez-Villanueva M., Ávalos-Nolazco D., Pérez-Ibarra K., Galindo-Rodríguez S., et al. Development of a Rapid Gold Nanoparticle-Based Lateral Flow Immunoassay for the Detection of Dengue Virus. Biosensors. 2022;12:495. doi: 10.3390/bios12070495.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bios12070495</ArticleId><ArticleId IdType="pmc">PMC9313084</ArticleId><ArticleId IdType="pubmed">35884298</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong N.-D., Nguyen-Phuoc K.-H., Mai-Hoang T.-D., Do K.-Y.T., Huynh T.-B., Nguyen N.-T.T., Tran T.L., Tran-Van H. Fabrication of Lateral Flow Immunoassay Strip for Rapid Detection of Acute Hepatopancreatic Necrosis Disease. 3 Biotech. 2022;12:243. doi: 10.1007/s13205-022-03311-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13205-022-03311-2</ArticleId><ArticleId IdType="pmc">PMC9402842</ArticleId><ArticleId IdType="pubmed">36033912</ArticleId></ArticleIdList></Reference><Reference><Citation>Trakoolwilaiwan T., Takeuchi Y., Leung T.S., Sebek M., Storozhuk L., Nguyen L., Tung L.D., Thanh N.T.K. Development of a Thermochromic Lateral Flow Assay to Improve Sensitivity for Dengue Virus Serotype 2 NS1 Detection. Nanoscale. 2023;15:12915–12925. doi: 10.1039/D3NR01858J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D3NR01858J</ArticleId><ArticleId IdType="pubmed">37427537</ArticleId></ArticleIdList></Reference><Reference><Citation>Abousenna M.S., Sayed R.H., Shaimaa A.E., Shasha F.A., El Sawy S.E.A., Darwish D.M. Sensitivity of Lateral Flow Technique for Diagnosis of Canine Parvovirus. Sci. Rep. 2024;14:5060. doi: 10.1038/s41598-024-55548-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-55548-x</ArticleId><ArticleId IdType="pmc">PMC10904390</ArticleId><ArticleId IdType="pubmed">38424259</ArticleId></ArticleIdList></Reference><Reference><Citation>de Puig H., Bosch I., Carré-Camps M., Hamad-Schifferli K. Effect of the Protein Corona on Antibody–Antigen Binding in Nanoparticle Sandwich Immunoassays. Bioconjug. Chem. 2017;28:230–238. doi: 10.1021/acs.bioconjchem.6b00523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.bioconjchem.6b00523</ArticleId><ArticleId IdType="pmc">PMC5245486</ArticleId><ArticleId IdType="pubmed">28095684</ArticleId></ArticleIdList></Reference><Reference><Citation>Paek S.-H., Lee S.-H., Cho J.-H., Kim Y.-S. Development of Rapid One-Step Immunochromatographic Assay. Methods. 2000;22:53–60. doi: 10.1006/meth.2000.1036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2000.1036</ArticleId><ArticleId IdType="pubmed">11020318</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Liu X., Wang C., Zhao Y., Hua F., Li C., Yang R., Zhou L. Evaluation of Up-Converting Phosphor Technology-Based Lateral Flow Strips for Rapid Detection of Bacillus Anthracis Spore, Brucella Spp., and Yersinia Pestis. PLoS ONE. 2014;9:e105305. doi: 10.1371/journal.pone.0105305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0105305</ArticleId><ArticleId IdType="pmc">PMC4140738</ArticleId><ArticleId IdType="pubmed">25144726</ArticleId></ArticleIdList></Reference><Reference><Citation>Latiano A., Tavano F., Panza A., Palmieri O., Niro G.A., Andriulli N., Latiano T., Corritore G., Gioffreda D., Gentile A., et al. False-Positive Results of SARS-CoV-2 IgM/IgG Antibody Tests in Sera Stored before the 2020 Pandemic in Italy. Int. J. Infect. Dis. 2021;104:159–163. doi: 10.1016/j.ijid.2020.12.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.12.067</ArticleId><ArticleId IdType="pmc">PMC7834192</ArticleId><ArticleId IdType="pubmed">33383223</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Du Q., Guo B., Mu D., Lu X., Ma Q., Guo Y., Fang L., Zhang B., Zhang G., et al. A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent Assays. J. Clin. Microbiol. 2020;58 doi: 10.1128/JCM.00375-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00375-20</ArticleId><ArticleId IdType="pmc">PMC7269408</ArticleId><ArticleId IdType="pubmed">32277023</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreira G.A., dos Santos E.H., Pereira M.F.B., Rodrigues K.A., Rocha M.C., Kanunfre K.A., Marques H.H.d.S., Okay T.S., Eisencraft A.P., Rossi Junior A., et al. Technical Performance of a Lateral Flow Immunoassay for Detection of Anti-SARS-CoV-2 IgG in the Outpatient Follow-up of Non-Severe Cases and at Different Times after Vaccination: Comparison with Enzyme and Chemiluminescent Immunoassays. Rev. Inst. Med. Trop. S. Paulo. 2022;64:e49. doi: 10.1590/s1678-9946202264049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1678-9946202264049</ArticleId><ArticleId IdType="pmc">PMC9281580</ArticleId><ArticleId IdType="pubmed">35858039</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedman K., Seppälä I. Recent Rubella Virus Infection Indicated by a Low Avidity of Specific IgG. J. Clin. Immunol. 1988;8:214–221. doi: 10.1007/BF00917569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00917569</ArticleId><ArticleId IdType="pubmed">3292566</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedman K., Lappalainen M., Söderlund M., Hedman L. Avidity of IgG in Serodiagnosis of Infectious Diseases. Rev. Res. Med. Microbiol. 1993;4:123. doi: 10.1097/00013542-199307000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00013542-199307000-00001</ArticleId></ArticleIdList></Reference><Reference><Citation>Correa V.A., Rodrigues T.S., Portilho A.I., Trzewikoswki de Lima G., De Gaspari E. Modified ELISA for Antibody Avidity Evaluation: The Need for Standardization. Biomed. J. 2021;44:433–438. doi: 10.1016/j.bj.2020.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2020.10.009</ArticleId><ArticleId IdType="pmc">PMC8515003</ArticleId><ArticleId IdType="pubmed">34493482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Lei Y., Lu X., Wang G., Du Q., Guo X., Xing Y., Zhang G., Wang D. Urea-Mediated Dissociation Alleviate the False-Positive Treponema Pallidum-Specific Antibodies Detected by ELISA. PLoS ONE. 2019;14:e0212893. doi: 10.1371/journal.pone.0212893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0212893</ArticleId><ArticleId IdType="pmc">PMC6400370</ArticleId><ArticleId IdType="pubmed">30835745</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J.Y., Burkert O., Mizaikoff B., Smiatek J. Impact of Urea on Monoclonal Antibodies: Multiple Destabilization and Aggregation Effects for Therapeutic Immunoglobulin G Proteins. ACS Omega. 2024;9:5517–5522. doi: 10.1021/acsomega.3c07323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.3c07323</ArticleId><ArticleId IdType="pmc">PMC10851413</ArticleId><ArticleId IdType="pubmed">38343970</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrman B.A., Leautaud V., Molyneux E., Richards-Kortum R.R. A Lateral Flow Assay for Quantitative Detection of Amplified HIV-1 RNA. PLoS ONE. 2012;7:e45611. doi: 10.1371/journal.pone.0045611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045611</ArticleId><ArticleId IdType="pmc">PMC3448666</ArticleId><ArticleId IdType="pubmed">23029134</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman D.G., Bland J.M. Statistics Notes: Diagnostic Tests 1: Sensitivity and Specificity. BMJ. 1994;308:1552. doi: 10.1136/bmj.308.6943.1552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.308.6943.1552</ArticleId><ArticleId IdType="pmc">PMC2540489</ArticleId><ArticleId IdType="pubmed">8019315</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman D.G., Bland J.M. Statistics Notes: Diagnostic Tests 2: Predictive Values. BMJ. 1994;309:102. doi: 10.1136/bmj.309.6947.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.309.6947.102</ArticleId><ArticleId IdType="pmc">PMC2540558</ArticleId><ArticleId IdType="pubmed">8038641</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis J.R., Koch G.G. The Measurement of Observer Agreement for Categorical Data. Biometrics. 1977;33:159–174. doi: 10.2307/2529310.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2529310</ArticleId><ArticleId IdType="pubmed">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheoran A.S., Holmes M.A. Separation of Equine IgG Subclasses (IgGa, IgGb and IgG(T)) Using Their Differential Binding Characteristics for Staphylococcal Protein A and Streptococcal Protein G. Vet. Immunol. Immunopathol. 1996;55:33–43. doi: 10.1016/S0165-2427(96)05618-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-2427(96)05618-8</ArticleId><ArticleId IdType="pubmed">9014304</ArticleId></ArticleIdList></Reference><Reference><Citation>Antigen-Detection in the Diagnosis of SARS-CoV-2 Infection.  [(accessed on 14 July 2024)].  Available online:  https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays.</Citation></Reference><Reference><Citation>Rondaan C., Gard L., Niesters H.G.M., van Leer-Buter C., Zhou X. COVID or No COVID: Interpreting Inconclusive SARS-CoV-2 qPCR Results in Different Populations and Platforms. J. Clin. Virol. Plus. 2023;3:100145. doi: 10.1016/j.jcvp.2023.100145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcvp.2023.100145</ArticleId><ArticleId IdType="pmc">PMC9997055</ArticleId><ArticleId IdType="pubmed">36941981</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed R.H., Abousenna M.S., Elsaady S.A., Soliman R., Saad M.A. Development of Lateral Flow Immunochromatographic Test for Rapid Detection of SARS-CoV-2 Virus Antigens in Clinical Specimens. Nanomaterials. 2022;12:2477. doi: 10.3390/nano12142477.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano12142477</ArticleId><ArticleId IdType="pmc">PMC9322925</ArticleId><ArticleId IdType="pubmed">35889701</ArticleId></ArticleIdList></Reference><Reference><Citation>D Souza S., Obeid W., Hernandez J., Hu D., Wen Y., Moledina D.G., Albert A., Gregg A., Wheeler A., Philbrook H.T., et al. The Development of Lateral Flow Devices for Urinary Biomarkers to Assess Kidney Health. Sci. Rep. 2024;14:8516. doi: 10.1038/s41598-024-59104-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-59104-5</ArticleId><ArticleId IdType="pmc">PMC11014899</ArticleId><ArticleId IdType="pubmed">38609491</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z.-X., Shi L.-C., Ran X.-Y., Li W., Wang X.-L., Wang F.-K. Development of a Lateral Flow Immunoassay for the Rapid Diagnosis of Invasive Candidiasis. Front. Microbiol. 2016;7:1451. doi: 10.3389/fmicb.2016.01451.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.01451</ArticleId><ArticleId IdType="pmc">PMC5020066</ArticleId><ArticleId IdType="pubmed">27679622</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan C.P.Y., Sum K.W., Cheung K.Y., Glatz J.F.C., Sanderson J.E., Hempel A., Lehmann M., Renneberg I., Renneberg R. Development of a Quantitative Lateral-Flow Assay for Rapid Detection of Fatty Acid-Binding Protein. J. Immunol. Methods. 2003;279:91–100. doi: 10.1016/S0022-1759(03)00243-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-1759(03)00243-6</ArticleId><ArticleId IdType="pubmed">12969550</ArticleId></ArticleIdList></Reference><Reference><Citation>Federation of Animal Sciences Societies . Guide for the Care and Use of Agricultural Animals in Research and Teaching. 3rd ed. Federation of Animal Science Societies; Champaign, IL, USA: 2010.</Citation></Reference><Reference><Citation>Expert Committee on Biological Standardization . WHO Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins. WHO; Geneva, Switzerland: 2016.</Citation></Reference><Reference><Citation>Committee for Proprietary Medicinal Products . Note for Guidance on Production and Quality Control of Animal Immunoglobulins and Immunosera for Human Use. EMEA; London, UK: 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>